Keywords
CoViD vaccine
Willingness to pay
Abstract
Introduction: Coronavirus disease(CoViD-19) remains pandemic globally. Vaccination is considered one of the best means to control both morbidity and mortality of CoViD-19. The study aims to find out the people's acceptance and willingness to pay for it. Method: The study used cross-sectional survey design. Data were collected using survey questionnaire from 1072 respondents (age 20-60 years) from 14 districts of Nepal. Socio-demographic characteristics of the respondents were independent and acceptance of vaccine was the dependent variable. Results: The study found that 84% of the respondents accepted CoViD vaccine. Only one out of six did not accept CoViD vaccine while 16% of the respondents stated that they would like to pay for CoViD vaccination. The average willingness to pay (WTP) for vaccination was NRs. 1053 (US$ 9) while median and mode remained the same NRs. 500. The middle age groups (30-49 years), respondents belonged to Madhesi, business people in terms of occupation, and the respondents who had completed school level education had a higher acceptance rate than other categories. It was observed that place of residence in terms of provinces or districts, age group, caste/ethnicity, and educational level of the respondents were significantly associated with the acceptance of CoViD vaccine. Conclusion: Appropriate information, education, and communication need to disseminate to minimize the misinformation about CoViD and lack of trust in vaccines that may lead to low acceptance and poor WTP for vaccines. These findings could be considered while making CoViD and CoViD vaccine-related interventions.
References
[2] N. Khanal and A. K. Singh, “Knowledge, attitude and practice regarding COVID-19 and its impact on dentistry: A cross-sectional survey among nepalese dentists,” Kathmandu Univ. Med. J., vol. 18, no. 2 70COVID-Special Issue, pp. 3–9, 2020, doi: 10.3126/kumj.v18i2.32937.
[3] K. P. Pathak, T. Gaire, and D. Acharya, “Novel coronavirus disease (Covid-19): Social distancing, isolation and quarantine are key success factors of Nepal’s public health practices or something else?,” Kathmandu Univ. Med. J., vol. 18, no. 2 COVID-19 Special Issue, pp. 68–74, 2020, doi: 10.3126/kumj.v18i2.33034.
[4] D. R. Singh, D. R. Sunuwar, K. Karki1, S. Ghimire, and N. Shrestha, “Knowledge and perception towards universal safety precautions during early phase of the COVID-19 outbreak in Nepal,” J. Community Health, vol. May, pp. 1–7, 2020, doi: 10.1007/s10900-020-00839-3.
[5] C. S. Wiysonge et al., “Vaccine hesitancy in the era of COVID-19: could lessons from the past help in divining the future?,” Hum. Vaccines Immunother., vol. 00, no. 00, pp. 1–3, 2021, doi: 10.1080/21645515.2021.1893062.
[6] J. H. Tibbetts, “Will a covid vaccine be accepted?,” Bioscience, vol. 71, no. 1, pp. 11–17, 2021, doi: 10.1093/biosci/biaa133.
[7] B. Lockyer et al., “Understanding COVID-19 misinformation and vaccine hesitancy in context: Findings from a qualitative study involving citizens in Bradford, UK,” Heal. Expect., no. 00, pp. 1–10, 2021, doi: 10.1111/hex.13240.
[8] J. F. Hair, W. C. Black, B. J. Babin, and R. E. Anderson, Multivariate Data Analysis, 7th ed. Harlow, London: Pearson Education Limited, 2014.
[9] B. Akarsu, D. Canbay Özdemir, D. Ayhan Baser, H. Aksoy, İ. Fidancı, and M. Cankurtaran, “While studies on COVID-19 vaccine is ongoing, the public’s thoughts and attitudes to the future COVID-19 vaccine,” Int. J. Clin. Pract., vol. 75, no. 4, pp. 1–10, 2021, doi: 10.1111/ijcp.13891.
[10] V. D. Tran et al., “Determinants of COVID-19 vaccine acceptance in a high infection-rate country: A cross-sectional study in Russia,” Pharm. Pract. (Granada)., vol. 19, no. 1, pp. 1–12, 2021, doi: 10.18549/PharmPract.2021.1.2276.
[11] A. Gagneux-Brunon et al., “Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: a cross-sectional survey,” J. Hosp. Infect., vol. 108, pp. 168–173, 2021, doi: 10.1016/j.jhin.2020.11.020.
[12] S. Sun, D. Lin, and D. Operario, “Interest in COVID-19 vaccine trials participation among young adults in China: Willingness, reasons for hesitancy, and demographic and psychosocial determinants,” Prev. Med. Reports, vol. 22, no. 101350, pp. 1–5, 2021, doi: 10.1016/j.pmedr.2021.101350.
[13] C. Wang et al., “Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: A national cross-sectional study,” Vaccine, vol. 39, no. 21, pp. 2833–2842, 2021, doi: 10.1016/j.vaccine.2021.04.020.
[14] M. Machida et al., “Acceptance of a covid-19 vaccine in japan during the covid-19 pandemic,” Vaccines, vol. 9, no. 3, pp. 1–11, 2021, doi: 10.3390/vaccines9030210.
[15] H. Chu and S. Liu, “Integrating health behavior theories to predict American’s intention to receive a COVID-19 vaccine,” Patient Educ. Couns., vol. xxxx, pp. 1–9, 2021, doi: 10.1016/j.pec.2021.02.031.
[16] E. Robinson, A. Jones, I. Lesser, and M. Daly, “International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples,” Vaccine, vol. 39, no. 15, pp. 2024–2034, 2021, doi: 10.1016/j.vaccine.2021.02.005.
[17] M. Daly and E. Robinson, “Willingness to vaccinate against COVID-19 in the U.S.: Representative longitudinal evidence from April to October 2020,” Am. J. Prev. Med., vol. 60, no. 6, pp. 766–773, 2021, doi: 10.1016/j.amepre.2021.01.008.
[18] E. Paul, A. Steptoe, and D. Fancourt, “Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications,” Lancet Reg. Heal. - Eur., vol. 1, pp. 1–10, 2021, doi: 10.1016/j.lanepe.2020.100012.
[19] B. J. Kuter et al., “Perspectives on the receipt of a COVID-19 vaccine: A survey of employees in two large hospitals in Philadelphia,” Vaccine, vol. 39, no. 12, pp. 1693–1700, 2021, doi: 10.1016/j.vaccine.2021.02.029.
[20] M. Schwarzinger, V. Watson, P. Arwidson, F. Alla, and S. Luchini, “COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics,” Lancet Public Heal., vol. 6, no. 4, pp. e210–e221, 2021, doi: 10.1016/S2468-2667(21)00012-8.
[21] S. Sun, D. Lin, and D. Operario, “Interest in COVID-19 vaccine trials participation among young adults in China: Willingness, reasons for hesitancy, and demographic and psychosocial determinants,” Prev. Med. Reports, vol. 22, no. July 2020, 2021, doi: 10.1016/j.pmedr.2021.101350.
[22] S. M. Saied, E. M. Saied, I. A. Kabbash, and S. A. E. F. Abdo, “Vaccine hesitancy: Beliefs and barriers associated with COVID-19 vaccination among Egyptian medical students,” J. Med. Virol., vol. 19, no. February, 2021, doi: 10.1002/jmv.26910.
[23] D. M. Ehde, M. K. Roberts, T. E. Herring, and K. N. Alschuler, “Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States,” Mult. Scler. Relat. Disord., vol. 49, no. December 2020, p. 102788, 2021, doi: 10.1016/j.msard.2021.102788.
[24] J. D. Ditekemena et al., “Covid-19 vaccine acceptance in the democratic republic of congo: A cross-sectional survey,” Vaccines, vol. 9, no. 2, pp. 1–11, 2021, doi: 10.3390/vaccines9020153.
[25] P. Verger and P. Peretti-Watel, “Understanding the determinants of acceptance of COVID-19 vaccines: a challenge in a fast-moving situation,” Lancet Public Heal., vol. 6, no. 4, pp. e195–e196, 2021, doi: 10.1016/S2468-2667(21)00029-3.
[26] M. Sallam, “Covid-19 vaccine hesitancy worldwide: A concise systematic review of vaccine acceptance rates,” Vaccines, vol. 9, no. 2, pp. 1–15, 2021, doi: 10.3390/vaccines9020160.